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Abstract
Background: A DNA prime, poxvirus (COPAK) boost vaccination regime with four antigens, i.e. a combination of
two Plasmodium knowlesi sporozoite (csp/ssp2) and two blood stage (ama1/msp142) genes, leads to self-limited
parasitaemia in 60% of rhesus monkeys and survival from an otherwise lethal infection with P. knowlesi. In the
present study, the role of the blood stage antigens in protection was studied in depth, focusing on antibody
formation against the blood stage antigens and the functionality thereof.
Methods: Rhesus macaques were immunized with the four-component vaccine and subsequently challenged i.v.
with 100 P. knowlesi sporozoites. During immunization and challenge, antibody titres against the two blood stage
antigens were determined, as well as the in vitro growth inhibition capacity of those antibodies. Antigen reversal
experiments were performed to determine the relative contribution of antibodies against each of the two blood
stage antigens to the inhibition.
Results: After vaccination, PkAMA1 and PkMSP119 antibody titres in vaccinated animals were low, which was
reflected in low levels of inhibition by these antibodies as determined by in vitro inhibition assays. Interestingly,
after sporozoite challenge antibody titres against blood stage antigens were boosted over 30-fold in both
protected and not protected animals. The in vitro inhibition levels increased to high levels (median inhibitions of
59% and 56% at 6 mg/mL total IgG, respectively). As growth inhibition levels were not significantly different
between protected and not protected animals, the ability to control infection appeared cannot be explained by
GIA levels. Judged by in vitro antigen reversal growth inhibition assays, over 85% of the inhibitory activity of these
antibodies was directed against PkAMA1.
Conclusions: This is the first report that demonstrates that a DNA prime/poxvirus boost vaccination regimen
induces low levels of malaria parasite growth inhibitory antibodies, which are boosted to high levels upon
challenge. No association could, however, be established between the levels of inhibitory capacity in vitro and
protection, either after vaccination or after challenge.
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Background
Malaria is a leading cause of morbidity and mortality
affecting billions of people worldwide. It is estimated
that malaria is responsible for the annual death of
800,000 people, mostly children under the age of five
[1]. In the face of increasing resistance of Plasmodium
parasites to anti-malarial (prophylactic) drugs, develop-
ment of an effective malaria vaccine is generally consid-
ered a public health priority [2]. Feasibility of a
successful malaria vaccine has been demonstrated by
immunization with irradiated sporozoites and subse-
quent malaria infection in rodent, non-human primate
and human models [3-5]. Furthermore, natural long-
term exposure to the parasite is associated with an age-
related decrease in the incidence, prevalence and density
of infection [6].
The traditional approach for malaria vaccine develop-
ment is based on recombinant proteins administered in
combination with novel adjuvants, directed either to
erythrocytic or pre-erythrocytic stages of the parasite.
Early clinical trials conducted with the pre-erythrocytic
particulate protein vaccine RTS,S showed moderate
levels of efficacy [7]. Protein subunit vaccines do have a
number of disadvantages. One is that they require the
use of adjuvants that may induce to adverse effects and
may be difficult to get access to, due to intellectual
property rights. Moreover, antigen conformation and
stability (with or without adjuvant) at ambient tempera-
tures are also major issues that may complicate the use
of subunit vaccines.
To circumvent these caveats, alternative vaccine deliv-
ery platforms have been developed. These include,
among others, viral vector approaches, DNA vaccination
and virosomal delivery systems, combinations of DNA
and viral vector in prime-boost strategies, and protein/
adjuvant booster strategies [8-13].
Previous studies with the malaria murine challenge
model have shown that DNA vaccines encoding Plasmo-
dium antigens are able to induce CD4+ and antibody
responses, as well CD8+, CTL and IFNg responses
required to attack parasites as they develop inside hepa-
tocytes [14-16]. Phase I/IIa clinical trials have estab-
lished the safety, tolerability and immunogenicity of
DNA vaccines encoding malaria parasite antigens in
healthy individuals [2,17].
A DNA prime (3x), poxvirus (COPAK) boost (1x) vac-
cination regimen comprising two sporozoite (csp/ssp2)
and two blood stage (ama1/msp142) antigens (Pk4x3/
COPAK) was developed at the Naval Medical Research
Centre. This reproducibly yields high levels (>60%) of
protection in the rhesus macaque/Plasmodium knowlesi
sporozoite challenge model [12,18,19]. The immunologi-
cal analysis of these studies [19] focused on the cellular
immune response. The parameter measured (IFN-g ELI-
spot) did not correlate with protection. It was noted
that immunization with a similar vaccine, containing
two sporozoite antigens (csp/ssp2), using the same
immunization schedule, resulted in a one-day delay in
the onset of parasitaemia, but not in protection. This
delay was not accompanied by lower parasite growth
rates in the blood stage, when compared to naive ani-
mals [19]. This suggested that protection is critically
depended on the blood stage antigens included in the
Pk4x3/COPAK vaccine. Therefore, in this study the
titres and functionality of the antibodies from blood
samples of the above studies (before and after challenge)
were analysed using ELISA and in vitro growth inhibi-
tion assays. Subsequently, GIA inhibition levels (after
vaccination and after challenge) were compared between
protected and not protected animals, in order to estab-
lish potential correlates of protection.
Methods
Plasmid DNA vaccines and poxvirus
The DNA plasmid and COPAK poxvirus immunization
vector (Virogenetics, Troy, N.Y) encoding two (csp/ssp2)
or four P. knowlesi genes (csp/ssp2/ama1/msp142) are
previously described. COPAK is derived from the
Copenhagen strain of vaccinia virus [12].
Antigen preparation
PkMSP119 was produced and purified as described pre-
viously [20]. PkAMA1 was expressed in Pichia pastoris
and produced as described previously [21]. Briefly, a
synthetic gene, comprising domain I-II-III of P. knowlesi
H strain AMA1 (Accession code XM_002259303) and a
hexa-histidine tag, codon optimized for expression in
Pichia pastoris (DNA20, Menlo Park, CA), was cloned
into the pPicZaA vector (Invitrogen, Leek, The Nether-
lands) and transformed into P. pastoris Km71H.
Rhesus monkeys, immunization regimen and challenge
The immunization and challenge phase of these studies
have been published, as well as the immunological
analysis focusing on the sporozoite antigens [19].
Briefly, in these studies three vaccination groups were
used: 1) a four antigen (Pk4) (csp/ssp2/ama1/msp142)
vaccine regimen, 2) a two antigen (csp/ssp2) vaccine
regimen, and 3) a control vaccine (mock vaccine; an
empty DNA plasmid and empty COPAK virus). The
immunization regimen included a prime with three
injections of DNA (dose of 0.5 mg of each plasmid in
a volume of 1 mL) given at day 0, 28, 56. Four months
later (day 168) the monkeys received a booster immu-
nization with 2 ×108 pfu of COPAK virus, for each
individual antigen [19].
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Three weeks after the COPAK booster (day 189), pre-
challenge blood samples were collected. One week later
(day 196), animals were challenged by intravenous injec-
tion of 100 P. knowlesi (H strain) sporozoites [19]. Ani-
mals were termed ‘protected’ when able to control the
parasitaemia below 1.5% and eventually to undetectable
levels, after challenge. Animals unable to control the
parasitaemia below 1.5% were treated with chloroquine
[19] and were termed ‘not protected’. A summary of the
outcomes is presented in Table 1. Four weeks after chal-
lenge (day 224), a final blood sample was taken. At day
224, animals not yet treated were given chloroquine.
ELISA
ELISA’s were performed in 96-well flat bottom micro
titre plates (Greiner, Alphen a/d Rijn, The Netherlands),
coated with either 0.5 μg mL-1 of PkMSP119 or
PkAMA1 according to published methods [22]. Titres
are expressed as arbitrary units (AU), where 1 AU yields
an optical density of 1.0 over background. Thus, the
AU-value of a sample is the reciprocal dilution at which
the absorbance at 405 nm equals 1.0. All assays were
performed in duplicate.
IgG purification
Total IgG was isolated on protein A columns (Sigma, St.
Louis, MO). Elution buffer was exchanged for RPMI
1640 by repeated concentration/dilution using Amicon
Ultra-15 concentrators (30-kDa cutoff; Millipore BV,
Amsterdam, The Netherlands). IgG fractions were filter
sterilized and stored at -20°C until use. IgG concentra-
tions were determined using a Nanodrop ND-1000
spectrophotometer (Nanodrop Technologies, Wilming-
ton, DE).
Parasite growth inhibition assay
The ability of protein A purified rhesus IgG to inhibit
in vitro parasite growth was assessed in triplicate using
96-well flat-bottomed tissue culture plates (Greiner,
Alphen a/d Rijn, The Netherlands) with in vitro matured















1 Mock* 20H 7 7.0 12 11.5
1 Mock 205 7 12
1 Mock AB07† 7 11
1 Mock AB58 7 12
1 Mock Q121 7 11
2 csp/ssp2 IIG 9 8.2 11 11.2
2 csp/ssp2 AB67 8 11
2 csp/ssp2 AC70 8 12
2 csp/ssp2 Q134 8 10
2 csp/ssp2 AK52 8 12
2 csp/ssp2 IIG 9 11
2 Pk4** 281 11 9.5 14 13
2 Pk4 284 9 13
2 Pk4 3000 9 13
2 Pk4 3129 9 13
2 Pk4 19159 9 13
2 Pk4 262 9 9.5 Never Never
2 Pk4 299 10 Never
2 Pk4 3086 11 Never
2 Pk4 3098 9 Never
2 Pk4 AB34 9 Never
1 Pk4 Q120 9 Never
1 Pk4 T152 10 Never
3 Pk4 228 10 Never
†Animal died before the end of the study. No post challenge sample was available.
*Mock, vaccine comprised of empty DNA vector and empty COPAK vaccinia virus.
**Pk4, vaccine comprised of four Plasmodium knowlesi antigens, csp/ssp2/ama1/msp142.
Day to 1st parasitaemia is the day of patency of parasites on thin smear. Day >1.5% parasitaemia is the day of drug treatment. All vaccinated animals were
primed with 3 DNA vaccine injections and boosted with recombinant poxviruses encoding the Pk4 antigens. Control (mock) animals received mock DNA vaccine
and empty poxvirus. Subjects were taken from three experiments (#1-3), under identical vaccination regimens.
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and synchronized P. knowlesi (H strain) schizonts at a
starting parasitaemia of 0.8-1.0%, a haematocrit of 2.0%,
in RPMI 1640 fortified with 10% normal human serum
and 20 μg mL-1 gentamicin, in a final volume of 100 μL.
For antigen reversal GIA experiments, PkAMA1 and
PkMSP119 antigens were dialyzed against RPMI 1640,
concentrated and filter-sterilized. Then they were seri-
ally diluted and incubated with isolated total rhesus IgG,
at a concentration that was determined to result in an
inhibition of 80% (in the absence of added antigens).
Incubation was in incomplete culture medium (total
volume 50 μL per well) for 45 min at room temperature,
followed by 15 min of incubation at 37°C in a 96-well
tissue culture plate. A parasite suspension containing
schizonts in culture medium with 40% normal human
serum was prepared and added to the plate to adjust
the cultures to the same parasitaemia and haematocrit
levels as used in the standard GIA described above.
After incubation of 24 to 26 hours, 30 μL of the resus-
pended culture was added to 200 μL ice-cold PBS, pH
7.4. After brief centrifugation, the supernatant was
removed and pellets were frozen. Parasite lactate dehy-
drogenase levels were determined in the thawed pellets,
as previously described [23]. From the pLDH levels,
parasite growth inhibition reported as percentage was
calculated as follows: 100-[(A650 of infected RBCs with
test IgG - A650 of uninfected RBCs)/(A650 of infected
RBCs with test IgG, at T = 0 - A650 uninfected RBCs, at
T = 0) × 100]. All GIA and reversal GIA results
reported are the averages of two independent GIA
assays.
Statistics
All statistical analyses were performed using R software
version 2.8.1 (R foundation for Statistical Computing,
Vienna, Austria). IgG titres were log-transformed to
obtain normality and significance was assessed by
t-tests; a correction for unequal variances was applied
where necessary. IgG antibody levels are presented as
geometric means with 95% confidence intervals. The
statistical significance of changes in IgG titres between
time points were assessed using a paired t-test and pre-
sented as a ratio with 95% confidence intervals. Between
group comparisons of GIA titres were performed using
Mann-Whitney U test and titres are presented as med-
ians with quartile ranges. Changes in GIA titres between
time points were assessed using a paired t-test and data
are presented as a difference (in percent points) with the
corresponding 95% confidence intervals. The relation
between GIA titre and PkAMA1 or PkMSP119 antibody
levels was assessed by Spearman’s rank correlation, the
correlation is presented as Spearman’s Rho. Two-sided
P values less than 0.05 were considered significant.
Results
This study is a further analysis of samples obtained dur-
ing a vaccination and challenge study, published by
Weiss and co-workers [19]. In that study, approximately
60% (8 out of 13) of monkeys were protected from chal-
lenge with P. knowlesi, after receiving three injections
with DNA encoding 4 Plasmodium knowlesi antigens
(csp/ssp2/ama1/msp142) and a booster with a mixture of
4 COPAK viruses, encoding the same antigens. Monkeys
receiving a similar vaccination regimen, but with DNA
and poxvirus comprising sporozoite antigens (csp/ssp2)
only, or mock vaccine, were not able to control the
parasitaemia (not protected). A summary of the out-
comes of this study is presented in Table 1.
Antibody responses induced by DNA prime/viral boost
vaccination
ELISA titres for the two blood stage antigens
(PkMSP119/PkAMA1) were determined in serum sam-
ples obtained from csp/ssp2 and csp/ssp2/ama1/msp142
animals, both before and after challenge, and run in a
single experiment (Figure 1, Table 2). Pre-immune sera
were all negative. Following Pk4x3 prime and poxvirus
(COPAK) booster vaccination, all monkeys serocon-
verted for both PkMSP119 and PkAMA1 antigens. Geo-
metric mean titre for PkMSP119 was 332 AU/mL (95%
CI: 97-1,136) while the titre for PkAMA1 appeared
higher at 2,305 AU/mL (95% CI: 855-6,214).
After vaccination, there were no significant differences
between the PkMSP119 and PkAMA1 antibody titres
from protected and non-protected monkeys, respectively
(T-test, P = 0.133 and P = 0.889, for PkMSP119 and
PkAMA1, respectively) (Figure 1, Table 2).
Four weeks after challenge, antibody levels to
PkAMA1 and PkMSP119 were boosted significantly. For
PkAMA1 the antibody level was 34 fold [95% CI: 15-80,
P = 9.9 e-7] higher post-challenge compared to pre-chal-
lenge. For PkMSP119 the increase in the antibody titre
after challenge was 50 fold [95% CI: 17-149, P = 4.2 e-6].
Again no significant differences were observed between
protected and not protected animals (PkMSP119; P =
0.94/PkAMA1; P = 0.35, t-test) (Figure 1, Table 2).
After challenge, control animals (mock-vaccinated)
showed elevated antibody levels against PkMSP119,
while no increase in anti-PkAMA1 levels was observed.
Before challenge, antibodies against PkAMA1 and
PkMSP119 were not detected in these animals (Figure 1).
Functionality of the antibodies
Growth inhibition assays were performed to assess the
functionality of the anti-blood stage antigen antibodies.
Plasma samples from 13 animals were selected from
previous Pk4 vaccination/challenge experiments with
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identical vaccination regimens [19]. These were divided
into two groups, comprised of protected (N = 8) or not
protected animals (N = 5). Samples from animals that
received a mock vaccine (N = 5) and from animals that
received csp/ssp2 vaccine (N = 5) were also included in
the analysis (Table 1).
Figure 2 shows the results of parasite growth inhibition
assays after vaccination (Panel A) and after challenge
(Panel B) of Pk4-vaccinated animals, csp/ssp2-vaccinated
animals and controls.
After vaccination, total IgG isolated from serum of
protected animals inhibited growth of P. knowlesi
Figure 1 ELISA titters against PkMSP119 and PkAMA1 before and after challenge. IgG antibody titres were measured by ELISA. The
superimposed box around the data points indicate the upper and lower quartiles, the line in the middle indicates the median value.
A) Antibody titres to PkMSP119 in the control (mock vaccine receiving) animals and Pk4-vaccinated animals (protected or not protected) before
challenge (left panel) and after challenge (right panel). B) Antibody titres to PkAMA1 in the control (mock vaccine receiving) animals and
vaccinated animals (protected or not protected) before challenge (left panel) and after challenge (right panel). Geometric shapes represent
individual animals in each group, throughout all figures. For one animal in the control group no post challenge data are available, as it died for
study-unrelated reasons.
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between -10 and 48% (median inhibition 5.3 at 6 mg/mL
IgG concentration). The animals with the highest
growth inhibition levels (31% and 48% at 6 mg/mL, cir-
cles in Figure 2) were able to control the infection. Vir-
tually no growth inhibitory antibodies were present in
total IgG fractions isolated from plasma samples from
animals that were not protected (Figure 2). No inhibi-
tion was observed using purified total IgG from plasma
samples from animals receiving the sporozoite antigen
vaccine or mock vaccine.
Four weeks after sporozoite challenge, a significant
increase of 51% ([95% CI: 41-61%], P = 1.1 e-7; paired t-
test) in the level of inhibition was observed in all Pk4
vaccinated animals (Figure 2). Purified total IgG isolated
from plasma samples from protected animals inhibited
parasite growth ranging from 14% to 80% (median inhi-
bition of 56% at 6 mg/mL IgG concentration), while not
protected animals had inhibition levels ranging from 21
to 80% (median inhibition of 59%).
GIA levels between protected and not protected ani-
mals were not significantly different (t-test), either
before (P = 0.07234) or after challenge (P = 0.8884).
This suggests that there is also no association between
GIA levels and protection.
Other studies have shown a positive correlation
between antibody levels and GIA inhibition (f.e. [24]). In
this study this correlation was confirmed, by Spearman’s
rank correlation test (for PkMSP119: rho = 0.683, P =
3.5 e-6; for PkAMA1: rho = 0.754, P = 8.7 e-7).
Purified total IgG from CSP/SSP2 vaccinated monkeys
and mock-vaccinated monkeys did not show any inhibi-
tion to P. knowlesi parasites in vitro, either before or
after challenge (Figure 2).
Specificity of the parasite growth inhibitory antibodies
The ability of PkAMA1 and PkMSP119 proteins to
reverse growth inhibition was evaluated in the in vitro
assay, in order to analyse the specificity of antibodies
induced by DNA prime, poxvirus boost vaccination and
P. knowlesi challenge. This was done using a pool of
total IgG isolated from plasma of protected animals
obtained after challenge and total IgG of a single
Table 2 Geometric means of antibody titres as determined by ELISA
All PkAMA1 Protected PkAMA1 Not protected PkAMA1 All PkMSP119 Protected PkMSP119 Not protected PkMSP119
Post
vaccination
2,305 [855-6,214] 2,417 [469-12,451] 2,137 [508-8,990] 332 [97-1,136] 633 [109-3,671] 118 [16-853]
Post challenge 79,030 [46,803-133,444] 94,870 [40,055-224,699] 59,000 [32,980-105,548] 16,784 [11,104-25,369] 17,875 [11,730-27,240] 15,175 [4,562-50,477]
In brackets the 95% confidence intervals. No significant differences were observed between protected or not-protected groups of animals. For both antigens and
all groups, antibody levels are significantly higher after challenge.
Figure 2 Parasite growth inhibition activity of protected and non-protected monkeys. A) Post vaccination B) post challenge. Mean GIA
inhibition levels of total IgG isolated from monkey serum from animals in control (mock) group, CSP/SSP2 group, and Pk4x3/COPAK vaccinated
animals (protected or not protected animals are shown). Final IgG concentration added to P. knowlesi parasite culture was 6 mg/mL. Geometric
shapes represent individual animals in each group, throughout all figures. For one animal in the control group no post challenge data are
available, as it died for study-unrelated reasons.
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protected animal (3086), also only after challenge. Anti-
bodies were pre-incubated with increasing concentra-
tions of PkAMA1 or PkMSP119, prior to addition to a
growth inhibition assay. Growth inhibition could be
reversed to over 85% by addition of the PkAMA1 anti-
gen at 100 μg/mL (Figure 3A). PkMSP119 protein, at the
same concentration, could only reverse inhibition by
10% (Figure 3B). The same degree of inhibition was
obtained with post-challenge IgG isolated from a plasma
sample of a single protected monkey (Figure 3). These
results show that in this assay the larger part of the
inhibitory activity is mediated by anti-PkAMA1
antibodies.
Discussion and conclusions
A DNA prime, poxvirus boost vaccination regimen that
has been shown to protect a high percentage of macaques
from potentially lethal parasitaemia after P. knowlesi
challenge [12,18,19] was further investigated. An impor-
tant question left open from these studies was the nature
of the immune response responsible for protection. Of
the four malaria antigens included in the Pk4 vaccine,
CSP and SSP2 are expressed on sporozoites and may be
present in the early stage infected liver cells [25,26].
Although AMA1 and MSP1 are generally considered to
be blood stage antigens [27,28], expression for both anti-
gens in late liver schizonts has been demonstrated
[29,30], while AMA1 is also expressed on the sporozoite
surface membrane [29]. Thus, both sets of antigens can
be considered to have added value as multi-stage vaccine
candidates.
Rhesus monkeys receiving csp and ssp2 only demon-
strated a delay in appearance of parasites in the blood
(>1 day), but were not able to control the infection
below 1.5% parasitaemia [19]. By contrast, monkeys that
received the Pk4x3/COPAK vaccine including ama1 and
msp142, showed a significant delay in the appearance of
parasites in the blood (>2 days) and 60% of these mon-
keys could control the infection below 1.5% parasitae-
mia. This is a strong indication that the immune
response to the blood stage antigens was necessary for
controlling parasite growth.
The cellular immune responses measured in the origi-
nal study [19] did not correlate with protection. As anti-
bodies are generally believed to be the key mediators for
protection against blood stage malaria, the antibody
responses to PkAMA1 and PkMSP119 after vaccination
were determined and found to be present at low levels,
with corresponding low growth inhibition activity (med-
ian inhibition 5.3% in protected animals versus -3.3% in
not protected animals). Challenge of the animals initially
resulted in high parasite growth rates, for all animals.
Obviously, in vivo parasite growth was not or only mar-
ginally inhibited. This is supported by the observation
that functional antibody levels after vaccination, as
determined in GIA, are low.
Although antibody levels against PkMSP119 and
PkAMA1 appear to be higher in protected animals com-
pared to those in not protected animals (Figure 1), the
differences are not statistically significant, likely to be
the result of the low values and corresponding high var-
iance of the data. Similarly, after vaccination there was
no correlation between the (low) GIA levels and protec-
tion. Low GIA values (<15% inhibition) are difficult to
interpret. For low inhibitions the two terms in the
upper part of the equation used to calculate the inhibi-
tion (See methods), are relatively large and nearly equal
to each other. A small deviation in either the control or
the sample value will have a strong impact on the mag-
nitude of the inhibition. The variance in the outcomes
of the growth experiments is also one of the reasons
why negative values are frequently observed in the GIA.
Sporozoite challenge boosted the levels of antibodies
against PkMSP119 and PkAMA1 in animals receiving
the Pk4 vaccines over 30 fold, but not in monkeys
receiving mock vaccines (Figure 1), supportive for the
hypothesis that DNA prime followed by a poxvirus
boost induces T-cell responses to the vaccine antigens.
The induced CD4 T-cells provide help to B-cells upon
(re-)exposure to the vaccine antigens, which may explain
the increase in PkAMA1 and PkMSP119 specific antibo-
dies during challenge.
Although antibody levels were significantly elevated
post challenge, no significant difference was observed
between the antibody levels of protected and not pro-
tected animals, either for PkAMA1 or for PkMSP119.
Similarly, GIA inhibitions were not significantly different
between protected and not protected animals after chal-
lenge (Figure 2).
The measured antibody titres and inhibition levels
(GIA), four weeks after challenge are lower than the
levels reported for PkAMA1/adjuvant immunization stu-
dies [21]. In these studies, even at high inhibition levels
(~70% inhibition at 6 mg/mL total IgG) some animals
were not able to control the infection. This is an indica-
tion that immune responses other than antibodies are
likely to be involved in protection.
Interestingly, PkMSP119 antibody levels were detected
after challenge of naïve monkeys, while PkAMA1 anti-
bodies were not (Figure 1). As in naturally exposed
humans in endemic areas the anti-PfAMA1 antibodies
titres are normally higher than those against PfMSP119,
[31,32], this may be explained by assuming that this is
the result of a single exposure to the parasite, reflecting
the difference in abundance of MSP1 and AMA1 on the
parasite’s surface, MSP1 being the most abundant pro-
tein on the merozoite surface, while AMA1 is poorly
abundant.
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Figure 3 Reversal of growth inhibitory activity by PkAMA1 and PkMSP119. Purified IgG from monkey 3086 (protected), post-challenge
(black triangle). Mixture of pool purified IgG taken from Pk4-vaccinated monkeys (262, 299, 3086, 3098, AB34, Q120, T152, 228), post-challenge
(black square). IgG was pre-incubated with either PkMSP119 (Panel A) or PkAMA1 (Panel B) in a five-fold serial dilution, prior to mixing with
P. knowlesi parasites. Results shown are the mean of two independent assays.
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In Figure 2, the values for the growth inhibition are
negative for most groups, indicative for a small stimula-
tion of growth in the presence of the antibodies that are
added. This observation is not uncommon, and, as
explained above, is related to the calculation of growth
inhibition.
Almost complete reversal of the growth inhibition can
be achieved by addition of 100 μg/mL PkAMA1 protein
in the GIA assay. Titration of PkMSP119 at the same
concentration of protein leads to approximately 10%
reversal of inhibition (Figure 3), implying that the larger
proportion of the (GIA) inhibitory antibodies in the sera
are directed against PkAMA1 rather than PkMSP119.
This observation does not necessarily imply that anti-
PkMSP119 antibodies do not contribute to the ability to
control the infection. It is known that several mechan-
isms of antibody-mediated inhibition exist, some with
the aid of immune cells (such as antibody dependent
cellular inhibition (ADCI) [33]) that will not give a
response in GIA. For anti-PfMSP119 antibodies, it has
been shown that Fc-tail mediated antibody responses
may be important for protection in a humanized mouse
model [34]. Moreover, part of the anti-MSP119 antibo-
dies may be growth-inhibitory rather than invasion inhi-
bitory [35]. These mechanisms may result in an
underestimating of the inhibitory capacity of the anti
PkMSP119 antibodies.
It has to be noted that all analyses of the response
against the PkMSP142 part of the vaccine was done
using PkMSP119 protein. It cannot be excluded that this
may have lead to an underestimation of the antibody
titres and of the ability to reverse the inhibition in the
GIA reversal experiments. However, a protein/adjuvant
immunization study with PfMSP142 in humans has
shown that the antibody response against PfMSP142 is
strongly directed to the PfMSP119 part [36], warranting
the conclusion that the main part of the GIA activity is
directed against PkAMA1.
The present study could not establish a correlation
between the levels of inhibitory antibodies, either before
or after challenge, with the ability to control the infec-
tion. Previous analysis of these experiments has shown
that also no correlation could be established between
T-cell mediated immunity (ELIspot antigen-induced
IFN-g production), and protection [19].
The boost in functional antibody levels observed after
sporozoite challenge is very interesting, especially in
relation with the observed course of parasitaemia in the
Pk4x3/COPAK vaccinated animals [19]. Boosting of
the antibody levels will, per definition, take place after
the parasites emerge from the liver and enter the circu-
lation, as only then the antigens will be “visible” for the
immune system. As the immune response against the
blood stage antigens is the determining factor for pro-
tection in this model, it can be imagined that the growth
rate of the parasites versus the increase over time in
inhibiting capacity of the immune system, irrespective of
the exact nature of this inhibiting capacity, determines
whether an animal will be protected or not. Obviously,
in protected animals the immune response is increasing
in magnitude over time, while the parasitaemia increases
to levels very near to 1.0%. The day the animals become
patent with parasites (day 11/12) parasites are multiply-
ing with a multiplication factor higher than one, result-
ing in higher parasitaemia the next day. Obviously the
inhibitory capacity of the immune system is not high
enough to arrest parasite multiplication. After two to
three days, in the protected animals parasite levels
become more or less constant, at 1% parasitaemia, and
it can be argued that the animals’ immune system has
been built up to an extent that the inhibition equals the
multiplication rate. In most protected animals this situa-
tion is maintained for a number of days, after which the
parasites are cleared from the circulation. In non-pro-
tected animals the immune system is obviously not able
to catch up with the growth of parasites. As P. knowlesi
has a multiplication rate of, on average, 10 per 24 hours
(one cycle) [37] (i.e. each ruptured schizont gives rise to
10 freshly infected RBCs), a value confirmed by the
parasitaemia profile of the controls (Figure 1A, in [19]),
the inhibition level at this point has to be close to 90%.
For some animals, protected or not, the levels of func-
tional antibodies, determined four weeks after challenge,
are not too far off of this value. This shows that anti-
body levels may be of key importance for protection for
some animals, but given the low inhibition values of
other protected monkeys, other immunological
responses may be of key importance for protection in
these animals. A final note, something that has not been
appreciated so far, is that the kinetics of the immune
response may be of great importance for the outcome of
an infection. The time it takes to reach the required
inhibition levels, in relation to the course of the infec-
tion, may be as important as the final magnitude. Fre-
quent, daily sampling (starting at the day of challenge)
may reveal whether (functional) antibody production
rates versus the course of the parasitaemia is correlated
with protection. Another interesting possibility would be
a second challenge, four weeks after the first, to investi-
gate whether the high levels of antibodies that are pre-
sent at that time may lead to protection of animals with
high functional antibody titres.
Importantly, this study shows that in a vaccination
regimen that is not focused on the production of antibo-
dies, these are produced and their levels are significantly
boosted after sporozoite challenge. These antibodies
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may play a direct role in protection alongside the cellu-
lar and antibody-mediated cellular immunity induced
after vaccination and challenge.
The above studies show that the P. knowlesi-rhesus
macaque challenge model could be instrumental for the
eventual elucidation of factors that contribute to protec-
tion upon challenge with P. knowlesi.
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